Welcome to our dedicated page for Iqvia Hldgs SEC filings (Ticker: IQV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how IQVIA turns billions of clinical data points into revenue can feel like decoding a medical registry. Key figures on contract research backlogs, technology licensing, and goodwill impairment are scattered across dense reports, and keeping up with IQVIA insider trading Form 4 transactions adds another layer of complexity. Investors who type “IQVIA SEC filings explained simply” need more than raw documents—they need answers. Stock Titan’s AI reads every line the moment it hits EDGAR and highlights what matters.
Whether you’re hunting for the latest IQVIA quarterly earnings report 10-Q filing, comparing cash-flow trends inside an IQVIA annual report 10-K simplified, or needing IQVIA Form 4 insider transactions real-time, our platform delivers. We pair line-by-line machine learning with human-trained models, turning raw data into plain-English takeaways. Drill into revenue by segment, R&D capitalization, or debt covenants in seconds—understanding IQVIA SEC documents with AI becomes straightforward. Each page also links to thorough IQVIA earnings report filing analysis prepared by our research desk, so you can move from numbers to narrative without opening a spreadsheet.
Looking beyond quarterly results, Stock Titan monitors every event that could move the share price. Receive instant alerts when IQVIA 8-K material events explained—think acquisitions, data breaches, or leadership changes—are posted. Explore IQVIA executive stock transactions Form 4 to gauge management sentiment, and review the IQVIA proxy statement executive compensation section to see how performance metrics align with pay. With real-time updates, AI-powered summaries, and historical search across all forms, you’ll spend less time digging and more time deciding.
IQVIA Holdings Inc. (IQV): Executive Vice President and General Counsel Eric Sherbet reported insider transactions on 10/29/2025. He exercised stock appreciation rights at $131.82 to acquire 10,000 shares, then sold 4,000 shares at a weighted average price of $219.70 (ranging from $219.66 to $219.92) and 6,000 shares at $219.72. Following these trades, he directly owns 21,108 shares. The SARs related to 10,000 underlying shares (exercisable since 02/13/2022, expiring 02/13/2029), with 8,436 derivative securities remaining beneficially owned.
IQVIA (IQV) insider transaction: On 10/29/2025, Chairman, Chief Executive Officer & President Ari Bousbib exercised stock appreciation rights for 77,592 shares at an exercise price of $59.90, then sold shares in multiple open‑market transactions. The reported weighted average sale prices ranged from $216.70 to $222.27 across the disclosed trade batches.
Following these transactions, Bousbib beneficially owned 807,163 shares directly. He also reported 543,302 shares held indirectly by a trust.
IQV (issuer) — Notice of proposed sale under Form 144. A shareholder filed to sell up to 56,557 shares of common stock, with an aggregate market value of $12,460,983.24. The approximate sale date listed is 10/29/2025, and the shares are listed on the NYSE. Morgan Stanley Smith Barney LLC is named as the broker.
The securities were acquired via Stock Appreciation Rights on 10/29/2025, with 56,557 shares indicated and cash noted as the nature of payment. The filing lists 170,300,000 shares outstanding, providing context for the potential sale size.
IQVIA Holdings (IQV) filed a Form 144 notice indicating an intended sale of 4,000 shares of common stock through Morgan Stanley Smith Barney LLC. The filing lists an aggregate market value of $878,819.60 for the planned sale, with an approximate sale date of 10/29/2025 on the NYSE.
The shares were acquired on 10/29/2025 via Stock Appreciation Rights from the issuer, with a stated amount acquired of 4,000 and cash as the nature of payment. The filing also notes 170,300,000 shares outstanding for context. Form 144 is a notice of proposed sale by an affiliate or other reporting person and does not, by itself, guarantee that a sale will occur.
IQVIA Holdings Inc. reported third‑quarter results with steady growth and active balance sheet management. Q3 2025 revenue was $4.1 billion versus $3.896 billion a year ago, and diluted EPS was $1.93 compared with $1.55. Segment revenue reached $1.631 billion in Technology & Analytics Solutions, $2.260 billion in Research & Development Solutions, and $209 million in Contract Sales & Medical Solutions. Q3 income from operations was $553 million. For the first nine months, revenue totaled $11.946 billion and diluted EPS was $4.86.
Operating cash flow for the nine months was $1.919 billion, supporting $1.032 billion of share repurchases (6.4 million shares). The company issued $2.0 billion of 6.250% senior notes due 2032 and amended its credit facilities, including a $1.985 billion Term B-5 loan to refinance prior tranches. Total debt principal was $15.034 billion and cash was $1.814 billion at quarter‑end. Remaining performance obligations were $34.4 billion, with about 30% expected to convert within 12 months. Goodwill increased to $15.948 billion, reflecting acquisitions. Common shares outstanding were 170.3 million as of October 20, 2025. Legal disputes with Veeva were fully resolved in August 2025 with no payment by either party.
IQVIA Holdings Inc. furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The full text of the release was posted on the company’s website and is included as Exhibit 99.1. Pursuant to General Instruction B.2, the Item 2.02 information is furnished, not filed, and is not subject to Section 18 of the Exchange Act or incorporated into other filings unless specifically referenced.
Harris Associates L.P. and Harris Associates, Inc. filed an Amendment No. 1 to Schedule 13G reporting beneficial ownership of IQVIA Holdings Inc. common stock. The filing shows an aggregate of 11,753,182 shares, representing 6.8% of the class, with sole voting power over 10,291,782 shares and sole dispositive power over 11,753,182 shares. The Schedule identifies IQVIA's principal executive office at 2400 Ellis Road, Durham, NC.
The statement notes the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The filing is dated as an event on 06/30/2025 and signed on 08/14/2025 by Joseph J. Allessie as General Counsel and Secretary.
FAQ
What is the current stock price of Iqvia Hldgs (IQV)?
What is the market cap of Iqvia Hldgs (IQV)?
